At Neurogen, we are committed to advancing the way of treating neurodegenerative Alzheimer's disease through groundbreaking microtissue brain implant technology.
Our Science
Our Commitment
Our Commitment
Neurogen’s proprietary technology develops an implantable microtissue which resembles the brain’s natural structure. This approach allow Neurogen’s microtissue to surpasses the capabilities of traditional cell therapies.
Our Commitment
Our Commitment
Our Commitment
Neurogen’s advanced approach ensures patient safety by eliminating potential harmful outcomes. We employ a minimally-invasive delivery system that eliminates the need for open skull surgery, ensuring efficient and rapid outcomes.
Our Team
Our Commitment
Our Team
We are a group of exceptionally committed scientists and technologists working relentlessly to solve the problem at hand. We are driven by the desire to innovate to break the traditional boundaries.
Company Overview
Neurogen Global Pty Ltd is a preclinical-stage biotechnology startup committed to developing innovative cell-based therapies to combat Alzheimer’s disease. Founded in 2023, we aim to leverage our cutting-edge advanced microtissue technology to restore brain function and improve the lives of patients affected by cortical atrophy in Alzheimer’s disease.
Our dedicated team of experts is working to advance breakthrough treatments, with the goal of transforming Alzheimer’s from incurable to curable and ensuring a healthy brain for all.